Skip to content
A Green Sign – Lifestyle
Author:
NEKTAR THERAPEUTICS
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
April 28, 2026
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 23, 2026
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
April 21, 2026
Nektar Therapeutics Announces Proposed Public Offering
April 20, 2026
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
April 20, 2026
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
April 19, 2026
←
Previous Page
1
2